Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 230

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 230
---
 and to propose, if necessary, changes to strategic or technical approaches; to advise management and guide the scientific direction in identifying strategies and selecting product candidates, based, in particular, on the scientific results obtained by us, including new targets and new compounds and to promote and advise Innate in the alliance strategies, such as external growth supporting synergies, including acquisition of new competences, purchase of operating rights, product candidates and innovative technologies. The Strategic Advisory Board is comprised of Aurélien Marabelle, Diane Mathis, Miriam Merad, Katy Rezvani, and Mario Sznol. Dr. Merad is the Chairman of the Strategic Advisory Board.

Aurélien Marabelle, M. D., Ph. D., is a medical oncologist and immunologist. His clinical practice is dedicated to early Phase clinical trials of cancer immunotherapies at the Gustave Roussy Cancer Center where he also leads a translational research laboratory dedicated to cancer immunology & immunotherapies (INSERM U1015 & CIC1428). He is a full professor of Clinical Immunology at the University of Paris Saclay, an active member of ESMO, ASCO, AACR, SITC, EATI and is the current vice-president and co-founder of the French Society for Cancer Immunotherapies (FITC). He has published more than 280 peer reviewed publications and has an H-index of 71.

Diane Mathis, obtained a Ph. D. from the University of Rochester and performed postdoctoral studies at the Laboratoire de Génétique Moléculaire des Eucaryotes in Strasbourg, France and Stanford University Medical Center. She returned to Strasbourg at the end of 1983, establishing a laboratory at the LGME (later the Institut de Genetique et de Biologie Moleculare et Cellulaire (IGBMC)) in conjunction with Dr. Christophe Benoist. The lab moved to the Joslin Diabetes Center in Boston in 1999. Through 2008, Dr. Mathis was a Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School (HMS), and Associate Research Director and Head of the Section on Immunology and Immunogenetics at Joslin. She is currently a Professor in the Department of Immunology at HMS and holder of the Morton

Grove-Rasmussen Chair in Immunohematology. She is also a Principal Faculty Member at the Harvard Stem Cell Institute and an Associate Faculty